| Literature DB >> 29076915 |
Meaghan A Magarik, Ronald C Walker, Jill Gilbert, H Charles Manning, Pierre P Massion.
Abstract
PET/CT imaging is frequently used for cancer diagnosis and restaging as metabolically active cells, including cancer, utilize glucose for proliferation. F-FDG is the most commonly utilized radiopharmaceutical in PET/CT imaging. Limitations of F-FDG imaging include intense physiologic uptake in benign tissues such as the brain and myocardium. We present a case of non-small cell lung cancer with myocardial and pericardial metastases obscured by physiologic F-FDG cardiac uptake but detected with the investigational PET radiotracer (4S)-4-(3-F-fluoropropyl)-L-glutamate (F-FSPG), which targets a pathway associated with glutathione biosynthesis. This case demonstrates the added value of F-FSPG PET/CT imaging.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29076915 PMCID: PMC5716866 DOI: 10.1097/RLU.0000000000001883
Source DB: PubMed Journal: Clin Nucl Med ISSN: 0363-9762 Impact factor: 7.794